The presence of intraductal carcinoma of prostate is a risk factor for poor pathologic response in men with high-risk prostate cancer receiving neoadjuvant therapy

被引：0
作者：
Binyu, W. [1 ]
Yao, F. [2 ]
Mengxia, C. [1 ]
Shan, P. [2 ]
Giancarlo, M. [3 ]
Junlong, Z. [1 ]
Shiwei, Z. [1 ]
Hongqian, G. [1 ]
Xuefeng, Q. [1 ]
机构：
[1] Nanjing Univ, Sch Med, Affiliated Nanjing Drum Tower Hosp, Dept Urol, Nanjing, Peoples R China
[2] Nanjing Univ, Sch Med, Affiliated Nanjing Drum Tower Hosp, Dept Pathol, Nanjing, Peoples R China
[3] San Giovanni Battista Hosp, Dept Urol, Turin, Italy
来源：
EUROPEAN UROLOGY | 2024年 / 85卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A0290
引用
收藏
页码：S1084 / S1084
页数：1
相关论文
共 50 条
  • [41] High-risk prostate cancer-classification and therapy
    Chang, Albert J.
    Autio, Karen A.
    Roach, Mack, III
    Scher, Howard I.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2014, 11 (06) : 308 - 323
  • [42] Competing Risk Analysis for Causes of Death in Men With High-Risk Prostate Cancer
    Hunter, G. K.
    Reddy, C. A.
    Stephans, K. L.
    Ciezki, J. P.
    Stephenson, A. J.
    Klein, E. A.
    Mahadevan, A.
    Kupelian, P. A.
    Tendulkar, R. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S414 - S414
  • [43] Radical Radiotherapy for High-Risk Prostate Cancer in Older Men
    Payne, Heather A.
    Hughes, Simon
    ONCOLOGIST, 2012, 17 : 9 - 15
  • [44] Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer
    Tewari, Alok K.
    Cheung, Alexander T. M.
    Crowdis, Jett
    Conway, Jake R.
    Camp, Sabrina Y.
    Wankowicz, Stephanie A.
    Livitz, Dimitri G.
    Park, Jihye
    Lis, Rosina T.
    Bosma-Moody, Alice
    He, Meng Xiao
    AlDubayan, Saud H.
    Zhang, Zhenwei
    McKay, Rana R.
    Leshchiner, Ignaty
    Brown, Myles
    Balk, Steven P.
    Getz, Gad
    Taplin, Mary-Ellen
    Van Allen, Eliezer M.
    CELL REPORTS, 2021, 36 (10):
  • [45] Neoadjuvant therapies for surgical management of high-risk, localized prostate cancer
    Mikkilineni, Nina
    Hyams, Elias S.
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S662 - S675
  • [46] Androgen Deprivation Therapy: A Survival Benefit or Detriment in Men With High-Risk Prostate Cancer?
    Fang, L. Christine
    Merrick, Gregory S.
    Wallner, Kent E.
    ONCOLOGY-NEW YORK, 2010, 24 (09): : 790 - 797
  • [47] Surgery for high-risk prostate cancer and metastatic prostate cancer
    Safir, Ilan J.
    Lian, Fei
    Alemozaffar, Mehrdad
    Master, Viraj A.
    CURRENT PROBLEMS IN CANCER, 2015, 39 (01) : 33 - 40
  • [48] Rationale for and Review of Neoadjuvant Therapy Prior to Radical Prostatectomy for Patients with High-Risk Prostate Cancer
    McKay, Rana R.
    Choueiri, Toni K.
    Taplin, Mary-Ellen
    DRUGS, 2013, 73 (13) : 1417 - 1430
  • [49] Phase 1 Trial of Neoadjuvant Radiation Therapy Before Prostatectomy for High-Risk Prostate Cancer
    Koontz, Bridget F.
    Quaranta, Brian P.
    Pura, John A.
    Lee, W. R.
    Vujaskovic, Zeljko
    Gerber, Leah
    Haake, Michael
    Anscher, Mitchell S.
    Robertson, Cary N.
    Polascik, Thomas J.
    Moul, Judd W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (01): : 88 - 93
  • [50] Rationale for and Review of Neoadjuvant Therapy Prior to Radical Prostatectomy for Patients with High-Risk Prostate Cancer
    Rana R. McKay
    Toni K. Choueiri
    Mary-Ellen Taplin
    Drugs, 2013, 73 : 1417 - 1430
12345